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Introduction
The development and use of antibiotics, since the second 
half of the twentieth century, has revolutionized the 
approach to the treatment and prevention of infectious 
diseases and of infections considered incurable in the 
past. However, although resources and energy have 
been invested in order to increase the knowledge 
about the mechanisms of resistance and in the search 
for increasingly effective molecules, the antibiotic 
resistance is currently faster than the development 
of new molecules  [1]. Antibiotic resistance is spread 
anywhere in the world, compromising the treatment 
of infectious diseases and undermining many other 
advances in health and medicine [2-5].
One of the most frequent conditions of antibiotic use is 
the Chronic Obstructive Pulmonary Disease (COPD). 
It is in fact known that the development of an infection 
in the bronchial tree is one of the most frequent causes 
of COPD exacerbations. Furthermore, more than half 
of the exacerbations are attributable to a bacterial 
infection [6]. 
The evidence shows that the use of antibiotics and 
corticosteroids strongly reduce the hospitalization 
rate during exacerbations  [7] and today the 
tendency is to prefer broad-spectrum antibiotics, 
given the increasing antibiotic resistance shown 
by Streptococcus pneumoniae and Haemophilus 
influenzae  [6]. However, multi-drug resistant bacteria 
(MDR) are increasingly common, especially in cases 
of exacerbation of the disease requiring intubation and 
mechanical ventilation. In fact t is well known that an 
overuse and misuse of antibiotics is responsible for 
most of the recent increases in antibiotic resistance [8]. 
The preventive use of bacterial lysates (such as OM-85 
BV) in reducing exacerbations in patients with COPD 
is well documented in several randomized controlled 
trials  [9]. OM-85 BV is the product of alkaline 
proteolysis of the following bacteria: Haemophilus 
influenzae, Streptococcus pneumoniae, Klebsiella 
pneumoniae, Klebsiella ozaenae, Staphylococcus 
aureus, Streptococcus pyogenes, Streptococcus viridans 
and Moraxella catarrhalis [10]. The effects of OM-85 
BV in patients with COPD and the cost effectiveness of 
this preventive treatment has been already investigated 
by other authors  [9,  11]. So, the aims of the present 
study were to update what has been already published 
in literature and, therefore, i) to perform a meta-
analysis on the efficacy of OM-85 BV in preventing 
acute exacerbations in patients with COPD and ii), to 
evaluate whether this preventive treatment can lead 
to significant savings for the National Health Service 
(NHS) thanks to an absolute reduction in the number 
of disease exacerbations.
Background. Chronic Obstructive Pulmonary Disease (COPD) 
is one of the most frequent pathologies in which antibiotics are 
used because 50% of the exacerbations are attributable to a 
bacterial infection. The aims of our study were: i) to perform a 
meta-analysis on the efficacy of the bacterial lysate OM-85 BV 
in preventing acute exacerbations in patients with COPD; ii) to 
evaluate whether this preventive treatment can lead to significant 
savings for the National Health Service (NHS).
Methods. A systematic research was conducted in the electronic 
database MEDLINE (PubMed) in June 2017-July 2020, collect-
ing evidences without time restrictions. Only randomized con-
trolled trials (RCTs) were included. The keywords used were 
“OM 85 BV AND chronic bronchitis” and “OM 85 BV AND 
COPD”. A cost-effectiveness analysis (CEA) was performed 
considering the costs for a treatment with OM-8BV, the costs 
for the treatment of an acute exacerbation and the number of 
prevented exacerbations.
Results. 59 publications were found, but the meta-analysis was 
conducted on 13 studies that met the inclusion criteria. OM-85 
BV is responsible of a statistically significant reduction in the 
mean number of COPD exacerbations (p < 0.01; WMD = -0.86; 
CI 95%: -1.38, -0.34) and in the days of antibiotic therapy (p < 0.01; 
WMD = -9.49; CI 95%: -11.93, -7.05). The cost-effectiveness ratio 
with a negative value is in favor to treatment.
Conclusions. OM-85 BV is effective in reducing exacerbations, 
and could lead to significant savings for the NHS. Moreover, 
reducing the number of exacerbations it could avoid an over-use 
of antibiotics and the consequent antibiotic resistance.
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A systematic research of peer-reviewed literature 
was conducted in the electronic database MEDLINE 
(PubMed) in the period June 2017-July 2020, collecting 
all the evidences without time restrictions. 
The keywords used were “OM 85 BV AND chronic 
bronchitis” and “OM 85 BV AND COPD”.
Inclusion criteria
Only Randomized Controlled Trials (RCTs) conducted on 
an adult population affected by COPD were considered 
suitable for the meta-analysis. Articles were included only 
if they contained clear and statistically assessable data on: 
i) average or absolute number of acute exacerbations; ii) 
total days of antibiotic therapy; iii) days of hospitalization. 
Other data useful to demonstrate or not the efficacy of 
OM-85 BV have been registered.
Studies that provided ambiguous or insufficient data 
were excluded.
Only studies written in English and French have been 
analyzed.
Study selection and data extraction
Studies were selected in a 2-stage process. First, titles 
and abstracts from electronic searches were scrutinised 
and then full manuscripts were analysed to select the 
eligible manuscripts according to the inclusion criteria. 
A further manual research analyzing the references of the 
articles was then carried out to avoid losing publications 
of a certain importance.
Statistics 
Statistical analysis was performed using Review 
Manager Version 5.2 (The Cochrane Collaboration, 
Software Update, Oxford, London).
Continuous variables have been described as averages 
and standard deviations (SD). The analysis of 
continuous variables was performed using the weighted 
mean difference (WMD), which indicates the difference 
between groups based on sample size. The significance 
level was set at P < 0.05.
To evaluate heterogeneity, the Higgins heterogeneity 
test or I2 test was used. The value of I2 describes the 
percentage of variability due to heterogeneity rather than 
a simple sampling error. In fact, I2 does not depend on 
the small number of the sample. “Low” heterogeneity is 
considered when the I2 value is less than 30%, moderate 
if between 30 and 50%, high if higher than 50%. When 
heterogeneity is described by an I2 above 30% it was 
decided to report the models with both “fixed” and 
“random” effects in order to emphasize the role of 
heterogeneity between studies. The difference between 
the two models consists in excluding or including the 
heterogeneity in the calculation of the overall estimate: 
the one with fixed effects excludes any heterogeneity, 
while the random effects model includes it; therefore, 
the overall estimate thus obtained will have wider 
confidence intervals.
In the case of low heterogeneity, both models give 
very similar results and for this reason it was decided 
to present the results only with random effects that are 
more conservative [12].
Specifically, variables analyzed through meta-analysis 
were: average and mean number of acute exacerbations, 
days of antibiotic therapy and of hospitalization, Severity 
score (the COPD severity score is based on responses 
to survey items that comprise five domains of COPD 
severity; the possible COPD severity score range is 0 to 35, 
with higher scores reflecting more severe disease) [13].
Cost-effective analysis (CEA)
The cost-effective analysis was performed following 
the same methodology used by Bergemann et al.  [9]. 
The estimation of cost for the management of severe 
or non-severe exacerbation was based on the results of 
an observational study evaluating the costs of chronic 
obstructive pulmonary disease in Italy (ICE Study - 
Italian Costs for Exacerbations in COPD) [14]. 
Dividing the average annual direct health cost of a patient 
with exacerbations (€ 2,423) by the average number of 
exacerbations [15, 16] the average cost of an exacerbation 
was calculated as equal to € 1,730. The average cost of 
a non-severe exacerbation was estimated by applying 
the same calculation methodology, but excluding the 
amount associated with hospital admission; it was thus 
obtained an amount of € 400.
For the cost-effectiveness analysis (CEA) the following 
formulas have been applied:
CM= CBV – (CTAE*PAE)
CER = [CBV – (CTAE*PAE)]/PAE
Where CM indicates the marginal costs, CER indicates 
the cost-effectiveness ratio (ie costs for each single 
prevented exacerbation), CBV indicates the costs for a 
treatment with OM-85 BV, CTAE indicates the costs for 
the treatment of an acute exacerbation and PAE indicates 
the number of prevented exacerbations.
Results
Bibliographic research yielded 59 publications. After 
the analysis of the titles and abstracts, 36 studies were 
excluded: 9 because they were duplicates, 6 because 
they were review, 16 because they focused on outcomes 
not in line with the present study, 9 because in other 
languages (2 in Russian, 3 in Polish, 1 in Romanian, and 
3 in German). Of the 19 remaining articles, the full text 
was analyzed: 1 article was excluded because review, 
1 excluded because editorial, 9 excluded because they 
focused on a population or outcome not in line with 
the study. After the analysis of the bibliographies it 
was decided to add, for completeness, 4 congress 
abstracts containing original data and 1 full text. The 
overall analysis was therefore conducted on 13 studies 
(Fig. 1). [17-29].
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The main characteristics of the studies included in the 
review with authors, year of publication, description of 
the treatment protocol, observation period, cases and 
controls and outcomes is shown in Table I.
The studies have been conducted between 1981 and 
2015 and involved a total of 1,366 patients undergoing 
treatment (range 33-192) and 1,282 undergoing placebo 
(range 20-192). The treated were aged 48.1-82 years, 
controls 48.4-82 years.
In 10 of the studies taken into consideration, the 
observation period was 6 months, in one 10 weeks, in 
one 22 weeks and in the last study 1 year.
Average number of exacerbations (Fig. 2)
The meta-analysis conducted on the 6 studies that 
reported these data demonstrates, using the random 
effects model, that OM-85 BV treatment is responsible 
for a statistically significant reduction in the average 
number of COPD exacerbations in the observation 
period (p < 0.01; WMD = -0.86; 95% CI: -1.38, -0.34).
Absolute number of exacerbations (Fig. 3)
The meta-analysis conducted on the 6 studies reporting 
these data shows, using the random effects model, that 
OM-85 BV treatment is a protective factor against 
the absolute number of COPD exacerbations in the 
observation period (p < 0.01; RR = 0.79; CI 95%: 0.70, 
0.90).
Days of antibiotic therapy (Fig. 4)
The meta-analysis conducted on the 4 studies reporting 
these data shows, using the random effects model, that 
OM-85 BV treatment is responsible for a statistically 
significant reduction in antibiotic therapy days in 
the observation period (p  <  0.01; WMD  =  -9.49; 
CI 95%: -11.93, -7.05).
Hospitalization days (Fig. 5)
The meta-analysis conducted on the 3 studies reporting 
these data shows, using the random effects model, 
that OM-85 BV treatment is responsible for a non-
statistically significant reduction in hospitalization days 
in the observation period (p  =  0.12; WMD  =  -7.28; 
CI 95%: -16.39, 1.83).
Severity Score (Fig. 6)
The meta-analysis conducted on the 2 studies that 
reported these data shows, using the random effects 
model, that the treatment with OM-85 BV is responsible 
for a non-statistically significant reduction of the 
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Fig. 1. Flow diagram for identifying studies to be included in the 
review.
Tab. I. Main characteristics of the studies included in the systematic review (T = treatment,  P = placebo; n.r. = not reported; *= conference 
abstract; SD = standard deviation; RCT = randomized controlled trial; A = 1 capsule per day for 30 days, 1 month without treatment, and then 
1 capsule/day for 10 days/month for 3 consecutive months; B = 1 capsule for 10 days/month for 3 consecutive months).
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Fig. 2. Meta-analysis of the average number of exacerbations.
Fig. 3. Meta-analysis of the absolute number of exacerbations.
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Cost-effective analysis
The OM-85 BV lysate recruitment protocols, as 
described in the studies included in our study, are two: 
i) one tablet a day of lysate for 30 days, followed by a 
period of 1 month suspension and then a 3 month period 
in which one tablet is taken a day only for the first 10 
days of the month; ii) one tablet a day for the first 10 
days of the month for three months. Considering that the 
price of OM-85 BV adults 30 tablets is equal to € 25 per 
pack[30], a treatment can cost from € 25 to € 50. The 
summary of the cost-effectiveness analysis is shown in 
the following figures (Figs. 7, 8).
Fig. 4. Meta-analysis of the days of antibiotic therapy.
Fig. 5. Meta-analysis of the hospitalization days.
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Fig. 6. Meta-analysis of the Severity Score.
Fig. 7. Cost-effectiveness analysis: (A) savings, in Euros, on an exacerbation with Hospitalization, (B) CER.
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Discussion
Acute exacerbations have a significant negative impact 
on several aspects of COPD, including the rapid decline 
in lung function, poor prognosis, impaired quality 
of life, and increased socioeconomic costs. Various 
studies have extensively shown that the prevention of 
acute recurrent exacerbations is able to slow down the 
progression of COPD [31]. Bacterial infections are the 
most common cause of exacerbation of the disease, 
contributing to 40% of all exacerbations [32]. This is the 
reason why the use of bacterial vaccines, such as those 
containing pneumococcal polysaccharides, is a highly 
recommended strategy for managing COPD [15].
The administered orally OM-85 BV (bacterial lysate 
obtained from eight pathogenic bacteria), is effective 
in preventing respiratory tract infections in adults and 
children.
In our study we conducted a meta-analysis of randomized 
clinical trials comparing the efficacy of OM-85 BV vs 
placebo. The most important parameters were the number 
of exacerbations in the months following the treatment 
and the days of antibiotic therapy. From the meta-
analysis of the analyzed studies, OM-85 BV treatment is 
responsible of a statistically significant reduction in the 
mean number of COPD exacerbations in the observation 
period (p  <  0.01; WMD  =  -0.86; CI 95%:  -1.38, 
-0.34) and also a statistically significant reduction in 
days of antibiotic therapy (p  <  0.01; WMD  =  -9.49; 
CI 95%: -11.93, -7.05). The cost-effectiveness analysis 
gathered the three elements: the cost of treatment with 
the lysate, the number of prevented exacerbations and 
the average cost of each exacerbation (for completeness 
divided into “with admission” and “without admission”).
Considering an average of 0.86 prevented exacerbations, 
treatment with OM-85 BV is responsible (applying 
the formula for calculating marginal costs) of a saving 
of € 1,513 in the case of exacerbation requiring 
hospitalization, and € 369 in the case of exacerbation that 
does not require hospitalization. The meta-analysis and 
cost-effectiveness analysis therefore confirm not only 
the efficacy of OM-85 BV in reducing the exacerbations, 
but highlight further positive effects of the lysate: in fact 
it allows a considerable saving for the National Health 
System (considering the almost 3 million patients 
affected in Italy) [33] and can improve the quality of life 
by reducing the number of infectious episodes. Reducing 
the number of exacerbations also slows the further 
progression of the disease towards respiratory failure, 
and avoids over-use of antibiotics and the consequent 
antibiotic resistance. The cost-effectiveness ratio with 
a strongly negative value is remarkably favorable to 
treatment.
The mechanisms that explain the effectiveness of OM-85 
Fig. 8. Cost-effectiveness analysis: (A) savings, in Euros, on an exacerbation without hospitalization, (B) CER 
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BV are not totally understood: it is supposed that it acts 
on the cells of the immune system and on the mediators 
of inflammation [34-36]. 
The theoretical basis for oral immunization is that the 
administered bacterial fractions can be recognized by 
the gut-associated lymphoid tissue (GALT), then they 
could activate the bronchial-associated lymphoid tissue 
(BALT) through cooperation and cellular traffic between 
these two systems  [37]. It should be remembered that 
the intestine is the largest organ producing antibodies 
and, in humans, more than 80% of activated B cells 
reside in the intestinal mucosa. Once the respiratory 
tract is reached, the B cells, transformed into plasma 
cells, release specific IgA which represent the most 
important form of defense against respiratory tract 
infections  [38]. In addition, the upregulation of the 
expression of the adhesion molecules of the phagocytes, 
the increase in the number and activity of T helper with 
an increase in the production of interferon gamma and 
CD4 +, and the increase in antibodies in the respiratory 
tract represent further mechanism activated after lysate 
administration [11, 36].
Mauel et al.  [35] demonstrated that lysates are able to 
increase the production of superoxide and nitrite anion 
by alveolar macrophages, enhancing microbicidal 
and cytolytic activity. In the same way they enhance 
the production of proinflammatory cytokines (tumor 
necrosis factor (TNF-)α, IL-8, IL-6, monocyte 
chemotactic protein (MCP) -1).
Finally, lysates are able to stimulate a Th1 response and 
increase the CD4 + / CD8 + cells ratio in the airways [39].
Our study has several limitations: as already highlighted 
by Pan et al. in their previous meta-analysis  [11], the 
enrolled patients were very different from each other 
(by age, ethnicity and stage of the disease), and this can 
contribute to increasing the risk of selection bias; the 
index of heterogeneity was high; for the hospitalization 
days and the Severity Score only few studies reported 
analyzable data. 
Moreover, one important limitation is the exiguous 
number of new studies on this topic that could add only a 
limited contribution to what has been already published 
in previous meta analyses [9, 11].
It is also important to say that vaccinations (such as the 
influenza vaccine) could prevent some exacerbations 
in patients with COPD  [40-42]: in fact, influenza is a 
frequent cause of exacerbations of chronic obstructive 
pulmonary disease (COPD) [43].
It is therefore possible to create an overlap between the 
protection provided by the influenza vaccine and that 
provided by the OM-85 BV which may alter the estimate 
of its real effectiveness.
Conclusions
Exacerbations in patients with COPD are associated 
with a more rapid deterioration of lung function, 
reduction of quality of life, and a prolongation of days 
of hospitalization and antibiotic therapy.
The meta-analysis conducted on randomized clinical 
trials in which the effect of lysate was compared with 
placebo partially updated what has been previously 
published in literature and confirmed the protective 
capacity of OM-85 BV against bacterial exacerbations 
in patients with COPD. The cost-effectiveness analysis 
subsequently carried out highlighted the considerable 
savings for the National Health Service deriving from 
the use of the lysate and, secondly, the reduction in the 
use of antibiotics, which are normally used in bacterial 
infections, can represent an additional strategy to contain 
the phenomenon of antibiotic resistance.
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